U.S., March 27 -- ClinicalTrials.gov registry received information related to the study (NCT06895538) titled 'Comparison of ATLG and ATG for Immune Reconstitution After Allo-HSCT for Hematologic Malignancy' on March 19.
Brief Summary: Allogeneic hematopoietic stem cell transplantation is the only curative treatment for malignant hematologic diseases. However, immune rejection is a major limitation in its application. In the "Beijing Protocol", the use of granulocyte colony-stimulating factor (G-CSF) in combination with anti-thymocyte globulin (ATG) can achieve "everyone has a donor". The use of ATG, however, can interfere with the recovery of immune function after transplantation, increasing the risk of life-threatening complications such ...